The Clinical Impact of the Cell-of-Origin Classification and the MYC+/BCL2+Double Expresser Status in DLBCL Treated within Prospective Clinical Trials of the Dshnhl

Staiger Annette M.; Ziepert Marita; Horn Heike; Scott David W.; Barth Thomas F. E.; Bernd Heinz-Wolfram; Feller Alfred C.; Klapper Wolfram; Hummel Michael; Stein Harald; Lenze Dido; Hansmann Martin-Leo; Hartmann Sylvia; Moeller Peter; Cogliatti Sergio; Lenz Georg; Truemper Lorenz H.; Loeffler Markus; Schmitz Norbert; Pfreundschuh Michael; Rosenwald Andreas; Ott German

首页> 外文期刊>Blood: The Journal of the American Society of Hematology >The Clinical Impact of the Cell-of-Origin Classification and the MYC+/BCL2+Double Expresser Status in DLBCL Treated within Prospective Clinical Trials of the Dshnhl

【24h】

The Clinical Impact of the Cell-of-Origin Classification and the MYC+/BCL2+Double Expresser Status in DLBCL Treated within Prospective Clinical Trials of the Dshnhl

机译：在Dshnhl的前瞻性临床试验中对起源细胞分类和DLBCL中MYC + / BCL2 +双重表达状态的临床影响

获取原文

获取原文并翻译 | 示例

获取外文期刊封面目录资料

开具论文收录证明 >>

文献代查 >>

文献数据库（团队版） >>

页面导航

著录项
引文网络
相似文献
相关主题

著录项

来源
《Blood: The Journal of the American Society of Hematology》 |2016年第22期|共5页
作者
Staiger Annette M.; Ziepert Marita; Horn Heike; Scott David W.; Barth Thomas F. E.; Bernd Heinz-Wolfram; Feller Alfred C.; Klapper Wolfram; Hummel Michael; Stein Harald; Lenze Dido; Hansmann Martin-Leo; Hartmann Sylvia; Moeller Peter; Cogliatti Sergio; Lenz Georg; Truemper Lorenz H.; Loeffler Markus; Schmitz Norbert; Pfreundschuh Michael; Rosenwald Andreas; Ott German;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. The Clinical Impact of the Cell-of-Origin Classification and the MYC+/BCL2+Double Expresser Status in DLBCL Treated within Prospective Clinical Trials of the Dshnhl [J] . Staiger Annette M., Ziepert Marita, Horn Heike, Blood: The Journal of the American Society of Hematology . 2016,第22期

机译：在Dshnhl的前瞻性临床试验中对起源细胞分类和DLBCL中MYC + / BCL2 +双重表达状态的临床影响
2. Clinical Impact of the Cell-of-Origin Classification and the MYC/BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group [J] . Staiger Annette M., Ziepert Marita, Horn Heike, Journal of Clinical Oncology . 2017,第22期

机译：德国高级非霍奇金淋巴瘤研究组前瞻性临床试验中弥漫性大B细胞淋巴瘤在弥漫性大B细胞淋巴瘤中的临床影响和MYC / BCL2双重患者的临床影响
3. Clinical and biological impact of TET2 mutations and expression in younger adult AML patients treated within the EORTC/GIMEMA AML-12 clinical trial [J] . AslanyanM.G., KroezeL.I., LangemeijerS.M.C., Annals of hematology . 2014,第8期

机译：在EORTC / GIMEMA AML-12临床试验中治疗的年轻成年AML患者中TET2突变和表达的临床和生物学影响
4. Translating Multiscale Cancer Models into Clinical Trials: Simulating Breast Cancer Tumor Dynamics within the Framework of the "Trial of Principle" Clinical Trial and the ACGT Project [C] . Eleni A. Kolokotroni, Georgios S. Stamatakos, Dimitra D. Dionysiou, IEEE International Conference on BioInformatics and BioEngineering . 2008

机译：将MultiSscale癌症模型转化为临床试验：在“原理试验”临床试验和ACGT项目的框架内模拟乳腺癌肿瘤动态
5. Fissure Caries Inhibition with Solea CO 2 -9.3μm Short-Pulsed Laser - A Randomized, Single Blind, Prospective, Split Mouth Controlled, Clinical Trial [D] . Kubitz, Maxwell. 2019

机译：Solea CO 2-9.3μm短脉冲激光抑制龋齿的发生-随机，单盲，前瞻性，分口控制的临床试验
6. A Multi-institutional Analysis of Diffuse Large B-cell Lymphoma (DLBCL) Treated with Consolidative Radiotherapy and the Impact of Cell-of-origin on Outcomes [O] . Chrishanthi Rajasooriyar, Jeremy Tey, Lea Choung Wong, 2019

机译：联合放疗治疗弥漫性大B细胞淋巴瘤（DLBCL）的多机构分析以及起源细胞对结局的影响
7. Cell-of-Origin (COO) Classification, BCL2 and MYC Expression Associated-Outcome in Younger Patients Treated By RCHOP Front-Line Therapy Versus Intensive Regimen Followed By Autologous Transplant for De Novo Advanced Diffuse Large B Cell Lymphoma (DLBCL) : Results of the French Prospective Multicenter Randomized Trial Goelams -075 [O] . Gaëlle Labouré, Marie-Cécile Parrens, Anjarasoa Tsaranazy, 2015

机译：通过RCHOP前线治疗治疗的年轻患者与密集方案治疗的年轻患者的患者的原产地（COO）分类，BCL2和MYC表达，其次是Novo先进的弥漫性大B细胞淋巴瘤（DLBCL）的自体移植：结果法国预期多中心随机试用Goelams -075

The Clinical Impact of the Cell-of-Origin Classification and the MYC+/BCL2+Double Expresser Status in DLBCL Treated within Prospective Clinical Trials of the Dshnhl

著录项

引文网络

相似文献

相关主题

期刊订阅